Jame Abraham describes the design of a phase 1 trial now investigating the novel LIV-1-targeted antibody–drug ladiratuzumab vedotin in patients with metastatic breast cancer (3:43).
30-05-2020 | ASCO 2020 | Conference coverage | Video
30-05-2020 | ASCO 2020 | Conference coverage | Video
Jame Abraham describes the design of a phase 1 trial now investigating the novel LIV-1-targeted antibody–drug ladiratuzumab vedotin in patients with metastatic breast cancer (3:43).